New eye drug faricimab aims to control wet AMD with fewer shots

NCT ID NCT07367282

Recruiting now Disease control Sponsor: Junyeop Lee Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 28, 2026 · Updated 4 times

Summary

This phase 4 trial will test the drug faricimab (Vabysmo) in 64 people with wet age-related macular degeneration (AMD). Participants will receive eye injections every 4 weeks for 4 doses, then a treat-and-extend schedule based on disease activity. The study also measures biomarkers in eye fluid to understand treatment response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Faricimab (Vabysmo) injection
What this could lead to: If successful, this could confirm faricimab as an effective treatment for wet AMD, potentially improving vision and reducing injection frequency.
What could go wrong: This is a small, single-arm, open-label trial with no placebo group, so results may be less reliable. Risks include eye infection, inflammation, and increased eye pressure from injections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MACULAR DEGENERATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

macular degeneration wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MACULAR DEGENERATION

Contacts and locations

Locations

Asan Medical Center
RECRUITING

Seoul, South Korea
Kyung Hee University Medical Center
NOT_YET_RECRUITING

Seoul, South Korea
Samsung Medical Center
RECRUITING

Seoul, South Korea
Seoul National University Bundang Hospital
RECRUITING

Seongnam, South Korea
Seoul St. Mary's Hospital
NOT_YET_RECRUITING

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.